The MiniMed Paradigm Veo system consists of a glucose sensor placed under the skin that continuously measures glucose levels, an insulin pump which delivers insulin continuously, and a transmitter which sends glucose level readings wirelessly from the sensor to the pump.

The system alerts the user if glucose levels become too high, too low, or if levels are rapidly changing. It can also predict whether levels will be too high or too low in the near future.

‘Frequent episodes’

An automated low glucose suspend function operates independently of the user and stops insulin delivery for two hours if the individual fails to respond to the alert.

The guidance recommends the system as an option for people with type 1 diabetes who experience frequent episodes of disabling hypoglycaemia despite “optimal management with insulin pump therapy”.

NICE states that “it is thought around 30 per cent of people with type 1 diabetes have problematic hypoglycaemia which can affect many aspects of daily life and result in significant anxiety”.

Type 1 charity JDRF think the announcement is a positive step.

Karen Addington, CEO from the organisation, said: “Hypos are what many people with type 1 diabetes hate most. They can rob people with the condition of a stress-free night’s sleep. We want everyone who could benefit from new technology to be able to get hold of it.”